[1] [3] The medication's appearance depends on its formulation and brand
The FDA granted accelerated approval in August 2025 for a new GLP-1-related indication, and the 2026 American Diabetes Association Standards of Care now recommend GLP-1 receptor agonists as preferred agents for specific patient groups
Semaglutide produced less weight loss than tirzepatide head-to-head, about 14% versus 20%. Its body-composition substudy measured a roughly 62:38 fat-to-lean loss split by mass, compared with about 75:25 for tirzepatide in a separate trial. The scan overstates muscle loss because lean mass includes water and organ tissue
Funding was provided by several organizations, including the Swedish Research Council, the Swedish Society for Medical Research, and the Novo Nordisk Foundation
WMD, weighted mean difference
Primes clinical insights report outlines where we are today and how things are shaping up for the future, demystifying trends like GLP-1s and supporting a whole-person approach to sustainable weight management